Sixth Acquisition Extends Veranex Lead in MedTech Industry Services

Veranex expands global capabilities for human-centered design, innovation, and strategy

RALEIGH, N.C.; Dec. 7, 2021 – Veranex, the only global, tech-enabled product development services provider focused on the medical technology industry, today announced its latest acquisition, Worrell, further expanding its offerings and geographic reach. As one integrated company, Veranex delivers compelling strategic, operational, and financial benefits by combining the skills and expertise needed for developing breakthrough medical technologies from concept to commercialization. Veranex is the product of six complementary acquisitions backed by growth investor Summit Partners: Ximedica, Quartesian, Boston Healthcare Associates, Experien Group, IMM Recherche, and now Worrell.

“The addition of Worrell strengthens Veranex’ offerings as the leading global provider in the medical device and biotech space. By enhancing our human-centered design capabilities with a focus on Phase 0 strategy, design conceptualization, and human factors services, we complement our existing ISO-certified Phase 1-4 engineering and pilot-scale manufacturing capabilities,” said Veranex Executive Chairman Patrick Donnelly. “We’re thrilled to welcome the employees of Worrell to Veranex,” added CEO David Dockhorn. “Kai Worrell joins Veranex as President of our product development and engineering business unit, with locations in Minneapolis, Providence, the San Francisco Bay Area, London, and Shanghai.”

“Worrell’s integration into Veranex comes at a perfect moment,” added Kai Worrell. “As medical device and biotech leaders around the world fuel their R&D pipelines, they need world class partners now more than ever. Adding Worrell’s 46 years of design expertise to the Veranex industry powerhouse will create new opportunities for improving global health outcomes.”

Technology Holdings served as financial advisors to Worrell for this transaction, and Saul, Ewing, Arnstein & Lehr LLP served as their legal counsel. McGuire Woods served as legal counsel to Veranex. Financial terms of the transaction were not disclosed.

Veranex has offices on four continents staffed by top designers and engineers as well as market access, regulatory, quality, and clinical experts providing support for full-scope MedTech development that includes:

• Product Design and Engineering
• Medial Device Evaluation Services
• Clinical Development Services
• Data Management and Analytics
• Regulatory Affairs and Quality Management
• Commercial Strategy and Market Access

Veranex also brings deep experience in a variety of clinical areas including cardiovascular disease, women’s health, oncology, and ophthalmology, and expertise across a range of technologies, from screening tests to therapeutic implants and monitoring devices.

Learn more about the comprehensive end-to-end pathway it takes to bring medical devices to market on the new Veranex company website.

About Veranex
Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept through to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time while its integrated and comprehensive solutions unify the entire development process. For more information, visit VeranexSolutions.com.